Trial Profile
Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Spartalizumab (Primary) ; Canakinumab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ElevatION:NSCLC-101
- Sponsors Novartis Pharmaceuticals
- 25 Jul 2022 Status changed from completed to discontinued.
- 09 Aug 2021 Status changed from active, no longer recruiting to completed.
- 06 May 2021 Planned End Date changed from 10 Dec 2021 to 16 Aug 2021.